Latest Transgenomic Inc (TBIO) Headlines Transgen
Post# of 54
Posted On: 03/11/2014 4:46:26 PM
Latest Transgenomic Inc (TBIO) Headlines
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"), a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million.
Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
Transgenomic Announces Issuance of Key U.S. Patent for ICE COLD-PCR
Business Wire - Tue Jan 21, 6:00AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent related to its licensed ICE COLD-PCR technology. The patent, titled "Full cold-PCR enrichment with reference blocking sequence", was assigned U.S. Patent No. 8,623,603 and is set to expire in 2031.
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests
Business Wire - Thu Jan 16, 6:19AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon's Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.
Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio
Business Wire - Thu Jan 16, 6:00AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has filed an application for listing its common shares on The NASDAQ Capital Market.
2013 Report on the International Molecular Diagnostics Markets
M2 - Mon Jan 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/82rrrq/molecular) has announced the addition of the "Molecular Diagnostics Markets" report to their offering. This report helps readers by Identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing. Readers will also obtain a complete understanding of the chief molecular diagnostics tests--i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; The research will help people discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; By focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts, readers will gain a thorough understanding of the molecular diagnostic market. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics and PCR Technology 3. Business Landscape for the Molecular Diagnostics Market Sectors 4. Overview of Clinical Molecular Diagnostic Platforms on the Market 5. Molecular Diagnostic Testing and Infectious Diseases 6. Cancer Detection Using Molecular Diagnostics 7. Genetics Testing in Molecular Diagnostics 8. Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics 9. Bioterrorism and Molecular Diagnostics 10. Regulatory Requirements 11. Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing 12. Company Profiles Companies Mentioned: - Abbott Laboratories - Beckman Coulter - Cancer Genetics, Inc - DiagnoCure, Inc - Exiqon - Genera Biosystems - Hologic - Illumina - Luminex - Myriad Genetics, Inc - Nanosphere - Orion Genomics - PerkinElmer Genetics - Progenika - QIAGEN NV - Roche Diagnostics - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - Siemens Healthcare Diagnostics (Siemens) - Spartan Bioscience - Thorne Diagnostics - Transgenomic - TrimGen - Trovagene, Inc - Veredus Laboratories - Veridex For more information visit http://www.researchandmarkets.com/research/82rrrq/molecular
Faruqi & Faruqi, LLP Launches An Investigation Against Transgenomic Inc. (TBIO) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Transgenomic Inc. ("Transgenomic" or the "Company") (OTC: TBIO) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for amendments to the Company's 2006 Equity Incentive Plan
Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit
Business Wire - Mon Nov 18, 6:30AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Stephen R. Miller has been named Senior Vice President and General Manager, Patient Testing.
Transgenomic Down 18.5%, Shares Slide into the Red (TBIO)
Comtex SmarTrend(R) - Fri Nov 08, 11:44AM CST
Transgenomic (NASDAQ:TBIO) is one of today's worst performing penny stocks, down 18.5% to $0.44 on 1.3x average daily volume. Thus far today, Transgenomic has traded 324,000 shares, vs. average volume of 255,000 shares per day. The stock has underperformed the Dow (-20.0% to the Dow's 0.6%) and underperformed the S&P 500 (-20.0% to the S&P's 0.9%) during today's trading.
Transgenomic Reports Third Quarter 2013 Financial Results
Business Wire - Wed Nov 06, 3:05PM CST
Transgenomic, Inc. (OTC/BB:TBIO) today reported financial results for the three and nine months ended September 30, 2013, and provided a business update.
Reminder: Transgenomic to Hold Third Quarter Financial Results Conference Call Today
Business Wire - Wed Nov 06, 8:00AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Inc partners with PerkinElmer Inc for oncology diagnostic test portfolio
M2 - Mon Nov 04, 7:24AM CST
Biotechnology company Transgenomic Inc (OTC Markets:TBIO) reported on Friday the launch of a partnership to market and distribute its oncology diagnostic test portfolio of products in territories outside the US.
Stock Reports on PGLO, HPTO and TBIO
ACCESSWIRE - Mon Nov 04, 12:04AM CST
Pan Global Corp (OTC: PGLO), Hopto Inc (OTC:HPTO) and Transgenomic Inc (OTC:TBIO) have been added to our watch list.
Transgenomic Signs Commercialization Collaboration with PerkinElmer for Oncology Diagnostic Test Portfolio
Business Wire - Fri Nov 01, 7:00AM CDT
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into a collaboration agreement with PerkinElmer, Inc.(NYSE
KI) a global leader focused on improving the health and safety of people and the environment, to market and distribute Transgenomic's oncology diagnostic test portfolio of products in territories outside the United States.
Transgenomic to Hold Third Quarter Financial Results Conference Call on November 6, 2013
Business Wire - Wed Oct 30, 8:25AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:
Transgenomic Announces Presentation of MD Anderson ICE COLD-PCR Clinical Data at 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Business Wire - Wed Oct 23, 8:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the results of a research collaboration with the MD Anderson Cancer Center employing the Company's ICE COLD-PCR technology platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free (cf) DNA present in the blood as were originally found in primary tumors. In addition, in a subset of patients who were followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.
PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test
PR Newswire - Tue Oct 15, 7:00AM CDT
PDI, Inc. (Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the signing of a U.S. collaboration agreement to commercialize CardioPredict(TM), a molecular diagnostic test developed by Transgenomic. CardioPredict(TM) is a broad-based genetic assay which identifies a patient's specific genes that influence the effectiveness and safety of many commonly used cardiovascular drugs.
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DGX' New Genetic Test for Opioid Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 9:30AM CDT
Recently, Quest Diagnostics introduced its latest lab-developed genetic test for the delivery of personalized opioid pain-relieving treatment.
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"), a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million.
Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
Transgenomic Announces Issuance of Key U.S. Patent for ICE COLD-PCR
Business Wire - Tue Jan 21, 6:00AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent related to its licensed ICE COLD-PCR technology. The patent, titled "Full cold-PCR enrichment with reference blocking sequence", was assigned U.S. Patent No. 8,623,603 and is set to expire in 2031.
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests
Business Wire - Thu Jan 16, 6:19AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon's Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.
Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio
Business Wire - Thu Jan 16, 6:00AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has filed an application for listing its common shares on The NASDAQ Capital Market.
2013 Report on the International Molecular Diagnostics Markets
M2 - Mon Jan 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/82rrrq/molecular) has announced the addition of the "Molecular Diagnostics Markets" report to their offering. This report helps readers by Identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing. Readers will also obtain a complete understanding of the chief molecular diagnostics tests--i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; The research will help people discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; By focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts, readers will gain a thorough understanding of the molecular diagnostic market. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics and PCR Technology 3. Business Landscape for the Molecular Diagnostics Market Sectors 4. Overview of Clinical Molecular Diagnostic Platforms on the Market 5. Molecular Diagnostic Testing and Infectious Diseases 6. Cancer Detection Using Molecular Diagnostics 7. Genetics Testing in Molecular Diagnostics 8. Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics 9. Bioterrorism and Molecular Diagnostics 10. Regulatory Requirements 11. Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing 12. Company Profiles Companies Mentioned: - Abbott Laboratories - Beckman Coulter - Cancer Genetics, Inc - DiagnoCure, Inc - Exiqon - Genera Biosystems - Hologic - Illumina - Luminex - Myriad Genetics, Inc - Nanosphere - Orion Genomics - PerkinElmer Genetics - Progenika - QIAGEN NV - Roche Diagnostics - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - Siemens Healthcare Diagnostics (Siemens) - Spartan Bioscience - Thorne Diagnostics - Transgenomic - TrimGen - Trovagene, Inc - Veredus Laboratories - Veridex For more information visit http://www.researchandmarkets.com/research/82rrrq/molecular
Faruqi & Faruqi, LLP Launches An Investigation Against Transgenomic Inc. (TBIO) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Transgenomic Inc. ("Transgenomic" or the "Company") (OTC: TBIO) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for amendments to the Company's 2006 Equity Incentive Plan
Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit
Business Wire - Mon Nov 18, 6:30AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Stephen R. Miller has been named Senior Vice President and General Manager, Patient Testing.
Transgenomic Down 18.5%, Shares Slide into the Red (TBIO)
Comtex SmarTrend(R) - Fri Nov 08, 11:44AM CST
Transgenomic (NASDAQ:TBIO) is one of today's worst performing penny stocks, down 18.5% to $0.44 on 1.3x average daily volume. Thus far today, Transgenomic has traded 324,000 shares, vs. average volume of 255,000 shares per day. The stock has underperformed the Dow (-20.0% to the Dow's 0.6%) and underperformed the S&P 500 (-20.0% to the S&P's 0.9%) during today's trading.
Transgenomic Reports Third Quarter 2013 Financial Results
Business Wire - Wed Nov 06, 3:05PM CST
Transgenomic, Inc. (OTC/BB:TBIO) today reported financial results for the three and nine months ended September 30, 2013, and provided a business update.
Reminder: Transgenomic to Hold Third Quarter Financial Results Conference Call Today
Business Wire - Wed Nov 06, 8:00AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Inc partners with PerkinElmer Inc for oncology diagnostic test portfolio
M2 - Mon Nov 04, 7:24AM CST
Biotechnology company Transgenomic Inc (OTC Markets:TBIO) reported on Friday the launch of a partnership to market and distribute its oncology diagnostic test portfolio of products in territories outside the US.
Stock Reports on PGLO, HPTO and TBIO
ACCESSWIRE - Mon Nov 04, 12:04AM CST
Pan Global Corp (OTC: PGLO), Hopto Inc (OTC:HPTO) and Transgenomic Inc (OTC:TBIO) have been added to our watch list.
Transgenomic Signs Commercialization Collaboration with PerkinElmer for Oncology Diagnostic Test Portfolio
Business Wire - Fri Nov 01, 7:00AM CDT
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into a collaboration agreement with PerkinElmer, Inc.(NYSE
KI) a global leader focused on improving the health and safety of people and the environment, to market and distribute Transgenomic's oncology diagnostic test portfolio of products in territories outside the United States. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 6, 2013
Business Wire - Wed Oct 30, 8:25AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:
Transgenomic Announces Presentation of MD Anderson ICE COLD-PCR Clinical Data at 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Business Wire - Wed Oct 23, 8:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the results of a research collaboration with the MD Anderson Cancer Center employing the Company's ICE COLD-PCR technology platform. This interim analysis demonstrates that in a high percentage of patients with advanced cancers, the same genetic mutations were detected in cell-free (cf) DNA present in the blood as were originally found in primary tumors. In addition, in a subset of patients who were followed over time, detection of mutations in cfDNA correlated with response to therapy or disease progression.
PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test
PR Newswire - Tue Oct 15, 7:00AM CDT
PDI, Inc. (Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the signing of a U.S. collaboration agreement to commercialize CardioPredict(TM), a molecular diagnostic test developed by Transgenomic. CardioPredict(TM) is a broad-based genetic assay which identifies a patient's specific genes that influence the effectiveness and safety of many commonly used cardiovascular drugs.
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DGX' New Genetic Test for Opioid Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 9:30AM CDT
Recently, Quest Diagnostics introduced its latest lab-developed genetic test for the delivery of personalized opioid pain-relieving treatment.
(0)
(0)Precipio, Inc. (PRPO) Stock Research Links
Scroll down for more posts ▼